- Home
- COSM vs NXTC Comparison
COSM vs NXTC Comparison
Compare COSM & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- NXTC
- Stock Information
- Founded
- COSM 2009
- NXTC 2015
- Country
- COSM Greece
- NXTC United States
- Employees
- COSM N/A
- NXTC N/A
- Industry
- COSM Other Pharmaceuticals
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- COSM Health Care
- NXTC Health Care
- Exchange
- COSM Nasdaq
- NXTC Nasdaq
- Market Cap
- COSM 8.2M
- NXTC 9.3M
- IPO Year
- COSM 2013
- NXTC 2019
- Fundamental
- Price
- COSM $0.43
- NXTC $0.39
- Analyst Decision
- COSM
- NXTC Strong Buy
- Analyst Count
- COSM 0
- NXTC 2
- Target Price
- COSM N/A
- NXTC $3.50
- AVG Volume (30 Days)
- COSM 749.7K
- NXTC 241.6K
- Earning Date
- COSM 04-16-2025
- NXTC 05-01-2025
- Dividend Yield
- COSM N/A
- NXTC N/A
- EPS Growth
- COSM N/A
- NXTC N/A
- EPS
- COSM N/A
- NXTC N/A
- Revenue
- COSM $54,426,402.00
- NXTC N/A
- Revenue This Year
- COSM $28.14
- NXTC N/A
- Revenue Next Year
- COSM N/A
- NXTC N/A
- P/E Ratio
- COSM N/A
- NXTC N/A
- Revenue Growth
- COSM 1.97
- NXTC N/A
- 52 Week Low
- COSM $0.28
- NXTC $0.22
- 52 Week High
- COSM $1.58
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- COSM 52.13
- NXTC 40.48
- Support Level
- COSM $0.40
- NXTC $0.34
- Resistance Level
- COSM $0.55
- NXTC $0.52
- Average True Range (ATR)
- COSM 0.06
- NXTC 0.06
- MACD
- COSM 0.01
- NXTC 0.01
- Stochastic Oscillator
- COSM 56.06
- NXTC 24.58
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.